Mark H. Eckman

Mark H. Eckman

Auto-generated profile, based on publicly available information

Mark H. Eckman

Division of General Internal Medicine and the Center for Clinical Effectiveness, University of Cincinnati, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Chest
Verified
Journal Article
Closed access
JDJames D. Douketis
James D. Douketis
ASAlex C. Spyropoulos
Alex C. Spyropoulos
FSFrederick A. Spencer
Frederick A. Spencer
MMMichael Mayr
Michael Mayr
AJAmir K. Jaffer
Amir K. Jaffer
RKRegina Kunz
Regina Kunz

1 February 2012 in Chest
Verified
Journal Article
Closed access
JYJohn J. You
John J. You
DSDaniel E. Singer
Daniel E. Singer
PHPatricia A. Howard
Patricia A. Howard
DLDeirdre A. Lane
Deirdre A. Lane
MEMark H. Eckman
Mark H. Eckman
Gregory LipGregory Lip
Gregory Lip

26 April 2004 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
JRJonathan Rosand
Jonathan Rosand
MEMark H. Eckman
Mark H. Eckman
KKKatherine A. Knudsen
Katherine A. Knudsen
DSDaniel E. Singer
Daniel E. Singer
SGSteven M. Greenberg
Steven M. Greenberg
Warfarin sodium remains a highly effective therapy for prevention of thromboembolic strokes in common clinical situations, especially atrial fibrillation.1-4 This protective effect of anticoagulation is in part offset by the risk of hemorrhagic complications, particularly intracerebral hemorrhage (ICH), the deadliest stroke subtype. Because of the poor outcome associated with warfarin-related ICH (warfarin-ICH), this complication has a large effect on the clinical decision of whether to administer anticoagulants.

1 July 2003 in Stroke
Verified
Journal Article
Closed access
MEMark H. Eckman
Mark H. Eckman
JRJonathan Rosand
Jonathan Rosand
KKKatherine A. Knudsen
Katherine A. Knudsen
DSDaniel E. Singer
Daniel E. Singer
SGSteven M. Greenberg
Steven M. Greenberg
Background and Purpose— Warfarin increases both the likelihood and the mortality of intracerebral hemorrhage (ICH), particularly in patients with a history of prior ICH. In light of this consideration, should a patient with both a history of ICH and a clear indication for anticoagulation such as nonvalvular atrial fibrillation be anticoagulated? In the absence of data from a clinical trial, we used a decision-analysis model to compare the expected values of 2 treatment strategies—warfarin and no anticoagulation—for such patients. Methods— We used a Markov state transition decision model stratified by location of hemorrhage (lobar or deep hemispheric). Effectiveness was measured in quality-adjusted life years (QALYs). Data sources included English language literature identified through MEDLINE searches and bibliographies from selected articles, along with empirical data from our own institution. The base case focused on a 69-year-old man with a history of ICH and newly diagnosed nonvalvular atrial fibrillation. Results— For patients with prior lobar ICH, withholding anticoagulation therapy was strongly preferred, improving quality-adjusted life expectancy by 1.9 QALYs. For patients with prior deep hemispheric ICH, withholding anticoagulation resulted in a smaller gain of 0.3 QALYs. In sensitivity analyses for patients with deep ICH, anticoagulation could be preferred if the risk of thromboembolic stroke is particularly high. Conclusions— Survivors of lobar ICH with atrial fibrillation should not be offered long-term anticoagulation. Similarly, most patients with deep hemispheric ICH and atrial fibrillation should not receive anticoagulant therapy. However, patients with deep hemispheric ICH at particularly high risk for thromboembolic stroke or low risk of ICH recurrence might benefit from long-term anticoagulation.

20 January 2009 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
MEMark H. Eckman
Mark H. Eckman
JRJonathan Rosand
Jonathan Rosand
SGSteven M. Greenberg
Steven M. Greenberg
BGBrian F. Gage
Brian F. Gage
Variants in genes involved in warfarin metabolism and sensitivity affect individual warfarin requirements and the risk for bleeding. Testing for these variant alleles might allow more personalized dosing of warfarin during the induction phase. In 2007, the U.S. Food and Drug Administration changed the labeling for warfarin (Coumadin, Bristol-Myers Squibb, Princeton, New Jersey), suggesting that clinicians consider genetic testing before initiating therapy. To examine the cost-effectiveness of genotype-guided dosing versus standard induction of warfarin therapy for patients with nonvalvular atrial fibrillation. Markov state transition decision model. MEDLINE searches and bibliographies from relevant articles of literature published in English. Outpatients or inpatients requiring initiation of warfarin therapy. The base case was a man age 69 years with newly diagnosed nonvalvular atrial fibrillation and no contraindications to warfarin therapy. Lifetime. Societal. Genotype-guided dosing consisting of genotyping for CYP2C9*2, CYP2C9*3, and/or VKORC1 versus standard warfarin induction. Effectiveness was measured in quality-adjusted life-years (QALYs), and costs were in 2007 U.S. dollars. In the base case, genotype-guided dosing resulted in better outcomes, but at a relatively high cost. Overall, the marginal cost-effectiveness of testing exceeded $170Â 000 per QALY. On the basis of current data and cost of testing (about $400), there is only a 10% chance that genotype-guided dosing is likely to be cost-effective (that is, <$50Â 000 per QALY). Sensitivity analyses revealed that for genetic testing to cost less than $50Â 000 per QALY, it would have to be restricted to patients at high risk for hemorrhage or meet the following optimistic criteria: prevent greater than 32% of major bleeding events, be available within 24 hours, and cost less than $200. Few published studies describe the effect of genotype-guided dosing on major bleeding events, and although these studies show a trend toward decreased bleeding, the results are not statistically significant. Warfarin-related genotyping is unlikely to be cost-effective for typical patients with nonvalvular atrial fibrillation, but may be cost-effective in patients at high risk for hemorrhage who are starting warfarin therapy. The National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Foundation for Informed Medical Decision Making; National Institutes of Neurological Disorders and Stroke; Deane Institute for Integrative Study of Atrial Fibrillation and Stroke; and American Heart Association.

1 January 2011 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
MEMark H. Eckman
Mark H. Eckman
DSDaniel E. Singer
Daniel E. Singer
JRJonathan Rosand
Jonathan Rosand
SGSteven M. Greenberg
Steven M. Greenberg
Background—: The rate of ischemic stroke associated with traditional risk factors for patients with atrial fibrillation has declined over the past 2 decades. Furthermore, new and potentially safer anticoagulants are on the horizon. Thus, the balance between risk factors for stroke and benefit of anticoagulation may be shifting. Methods and Results—: The Markov state transition decision model was used to analyze the CHADS 2 score, above which anticoagulation is preferred, first using the stroke rate predicted for the CHADS 2 derivation cohort, and then using the stroke rate from the more contemporary AnTicoagulation and Risk Factors In Atrial Fibrillation cohort for any CHADS 2 score. The base case was a 69-year-old man with atrial fibrillation. Interventions included oral anticoagulant therapy with warfarin or a hypothetical “new and safer” anticoagulant (based on dabigatran), no antithrombotic therapy, or aspirin. Warfarin is preferred above a stroke rate of 1.7% per year, whereas aspirin is preferred at lower rates of stroke. Anticoagulation with warfarin is preferred even for a score of 0 using the higher rates of the older CHADS 2 derivation cohort. Using more contemporary and lower estimates of stroke risk raises the threshold for use of warfarin to a CHADS 2 score ≥2. However, anticoagulation with a “new, safer” agent, modeled on the results of the Randomized Evaluation of Long-Term Anticoagulation Therapy trial of dabigatran, leads to a lowering of the threshold for anticoagulation to a stroke rate of 0.9% per year. Conclusions—: Use of a more contemporary estimate of stroke risk shifts the “tipping point,” such that anticoagulation is preferred at a higher CHADS 2 score, reducing the number of patients for whom anticoagulation is recommended. The introduction of “new, safer” agents, however, would shift the tipping point in the opposite direction.